** South Korea's pharmaceutical and biotechnology firms
rise; pharmaceutical index .KS32 rises 2.8 pct
** Country's top financial regulator said on Wednesday it
had revised accounting rule guideline, easing market uncertainty
** The Financial Services Commission (FSC) said it would
allow companies to correct accounting errors and treat research
and development (R&D) spending as an asset if a new drug is
technically viable, under specific standards
** Shares of Samsung Biologics Co Ltd 207940.KS and Hanmi
Pharm Co Ltd 128940.KS climb 4.7 pct and 2.8 pct,
respectively, while pharmaceutical giant Celltrion Inc
068270.KS gains as much as 1.8 pct
** Samsung Biologics also boosted by a recent rise in sales
contracts, says Kang Yang-ku, an analyst at Hyundai Motor
Investment & Securities
** Broader market .KS11 up 0.7 pct as of 0233 GMT
((joori.roh.thomsonreuters.com@reuters.net))